Get the Stockscreener App
545.96
0.10%
0.56
After Hours:
545.96
United Therapeutics Corp stock is traded at $545.96, with a volume of 431.35K.
It is up +0.10% in the last 24 hours and down -6.15% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
See More
Previous Close:
$545.40
Open:
$547.59
24h Volume:
431.35K
Relative Volume:
0.86
Market Cap:
$23.17B
Revenue:
$3.17B
Net Income/Loss:
$1.29B
P/E Ratio:
20.15
EPS:
27.0947
Net Cash Flow:
$1.01B
1W Performance:
-0.71%
1M Performance:
-6.15%
6M Performance:
+10.52%
1Y Performance:
+90.80%
1-Day Range:
$536.39
$547.59
1-Week Range:
$536.39
$557.97
52-Week Range:
$272.12
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
545.96 | 23.17B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 40.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.13 | 40.31B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.57 | 33.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Underweight |
| Sep-26-25 | Initiated | RBC Capital Mkts | Outperform |
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics CFO Edgemond sells $5.49m in company stock By Investing.com - Investing.com Australia
United Therapeutics CFO Edgemond sells $5.49m in company stock - Investing.com
Neuroblastoma Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Y-mAbs Therapeutics, United Therapeutics Corp, EUSA Pharma, Clarity Pharma, Eli Lilly - Barchart.com
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.2m in stock - Investing.com
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns - The Motley Fool
United Therapeutics CEO Rothblatt sells $5.2m in shares By Investing.com - Investing.com Canada
United Therapeutics CEO Rothblatt sells $5.2m in shares - Investing.com
United Therapeutics CFO James Edgemond sells $5.48m in stock - Investing.com
United Therapeutics CFO James Edgemond sells $5.48m in stock By Investing.com - Investing.com Australia
Goodwin Advises Ascidian Therapeutics On A Global Research Collaboration With Eli Lilly For Up To $1.9 Billion - Mondaq
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in stock By Investing.com - Investing.com Nigeria
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in stock - Investing.com
United Therapeutics Corporation (UTHR) Stock Analysis: Investor Outlook on Robust Growth Potential with 20.98% Upside - DirectorsTalk Interviews
United Therapeutics CEO Rothblatt sells $5.47m in stock - Investing.com
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report? - Yahoo Finance
How The Story Around United Therapeutics (UTHR) Is Shifting On Trials Pricing And Valuation - Yahoo Finance
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
United Therapeutics EVP Mahon sells $4.54 million in stock - Investing.com UK
United Therapeutics Q1 2026 slides: IPF breakthrough offsets revenue miss - Investing.com
MannKind stock surges on United Therapeutics partnership deal - Investing.com
United Therapeutics EVP Mahon sells $4.54 million in stock By Investing.com - Investing.com Australia
United Therapeutics stock hits all-time high at 608.87 USD - Investing.com
UTHR Technical Analysis & Stock Price Forecast - Intellectia AI
UTHR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tectonic Therapeutic Stock Climbs as Broader Market Sinks - Bez Kabli
Xenotransplantation Explained: How Animal Organs Could Transform Medicine - News-Medical
Acute Respiratory Distress Syndrome Market to Grow - One News Page
Rothblatt (United Therapeutics) sells $5.3m in UTHR stock - Investing.com
Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - The Manila Times
United Therapeutics CFO James Edgemond sells $5.48m in shares - Investing.com UK
United Therapeutics CEO Rothblatt sells $863,947 in stock By Investing.com - Investing.com Nigeria
United Therapeutics CEO Martine Rothblatt sells $5.2m in company stock - Investing.com Nigeria
United Therapeutics CFO James Edgemond sells $5.48m in shares By Investing.com - Investing.com India
United Therapeutics CEO Rothblatt sells $863,947 in stock - Investing.com
United Therapeutics CEO Martine Rothblatt sells $5.2m in company stock By Investing.com - Investing.com South Africa
Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors? - The Motley Fool
Simplify Health Care ETF (PINK) vs. Vanguard Health Care ETF (VHT): A Detailed ComparisonNews and Statistics - IndexBox
Liquidia Sinks 5% After Recent Rally - Bez Kabli
United Therapeutics Corporation (UTHR) Stock Analysis: Exploring a 19.47% Potential Upside - DirectorsTalk Interviews
United Therapeutics Corporation (UTHR): Renaissance Technologies Likes This Biotech Stock - Insider Monkey
United Therapeutics CEO Rothblatt exercises, sells $5.37m in stock By Investing.com - Investing.com Australia
United Therapeutics CEO Rothblatt exercises, sells $5.37m in stock - Investing.com UK
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EDGEMOND JAMES | CFO AND TREASURER |
Jun 11 '26 |
Sale |
549.29 |
10,000 |
5,492,894 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 11 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 11 '26 |
Sale |
549.23 |
9,500 |
5,217,684 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 10 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 10 '26 |
Sale |
545.83 |
9,500 |
5,185,365 |
40,513 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 09 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 09 '26 |
Sale |
549.32 |
9,500 |
5,218,534 |
40,513 |
| EDGEMOND JAMES | CFO AND TREASURER |
Jun 08 '26 |
Option Exercise |
117.76 |
10,000 |
1,177,600 |
28,876 |
| EDGEMOND JAMES | CFO AND TREASURER |
Jun 08 '26 |
Sale |
547.50 |
10,000 |
5,475,045 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 08 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
1.04%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):